BiogenBIIB
Recorded

Biogen 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration1 hr 8 minParticipants17

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Please stand by. We're about to begin. Good morning. My name is Jess, and I will be your conference operator today. At this time, I would like to welcome everyone to the Biogen second quarter 2026 earnings call and business update. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star one on your telephone keypad. Please limit yourself to one question to allow other participants time for questions. If you require any further follow-up, you may press star one again to rejoin the queue. Today's conference is being recorded. Thank you. I would now like to turn the conference over to Mr. Tim Power, Head of Investor Relations. Mr. Power, you may begin your conference.

Tim PowerHead of Investor Relations

Thanks, Jess, and good morning, everyone. Welcome to Biogen's second quarter 2026 earnings call. During this call, we'll make forward-looking statements which involve risks and uncertainties that may cause actual results to differ materially from our forward-looking statements. We provide a comprehensive list of risk factors in our SEC filings, which I encourage you to review. Our earnings release and other documents related to our results, as well as reconciliations between GAAP and non-GAAP results discussed on this call can be found in the investor section of biogen.com. We've also posted slides to our website that will be used during the call. On today's call, I'm joined by our President and Chief Executive Officer, Chris Viehbacher; Dr. Priya Singhal, Head of Development; and Robin Kramer, our Chief Financial Officer. Alisha Alaimo, President of North America, will also be available for the Q&A section of the call.

Tim PowerHead of Investor Relations

We'll make some opening comments, and we'll move to Q&A. To allow us to get through as many questions as possible, we kindly ask that you limit yourself to just one question. I'll now turn the call over to Chris.

Chris ViehbacherPresident and CEO

Portfolio with the goal of achieving sustainable revenue growth. If I take the three elements that I think contribute to that is first is our growth product portfolio. Now, even before we include the products from Apellis, we've seen significant growth, and in fact, our growth portfolio now is greater than our legacy MS portfolio. That's really been most recently enhanced by two important achievements. The first is SPINRAZA high dose where we've seen across all markets. The first market to be approved was in Japan, then Europe, and now the U.S., and we're starting to see this roll out into more international markets. In all of those markets, this conversion has gone much faster than we expected, and that's an important development for us because this is an extremely competitive market where efficacy matters, and we've seen considerable efficacy benefits come from the high dose of SPINRAZA.

Chris ViehbacherPresident and CEO

This is a franchise that we see for the longer term because we've got salanersen coming along behind that. Maintaining market share and in fact, what we're seeing is some anecdotal switch backs particularly from the oral product to SPINRAZA. It's important not only for the quarter, but important for the franchise longer term. The second major achievement this quarter was really LEQEMBI IQLIK. It's the first of its kind Alzheimer's treatment, so now offering home dosing for both initiation and maintenance. I think there's probably two opportunities in particular here, maybe even three. The first is obviously with the biweekly infusion. A number of physicians are thinking carefully about which patients are actually going to be eligible for treatment.

Chris ViehbacherPresident and CEO

If they don't think that the patient can get there on their own, or there's not a caregiver who's prepared to take the time to get that patient to the infusion centers those patients are often not offered treatment. This should perhaps make it easier for a broader section of patients to become eligible for treatment. We think also that there could be a benefit in maintaining patients longer on therapy. Finally we think there's a competitive advantage because the benefit that the competitor has with once monthly dosing now seems to be much less when you've got a home subcutaneous option for them. The second element of the sustainable growth is our pipeline, and we'll come on and talk about that in a few minutes. The third element is really SYFOVRE and EMPAVELI from the acquisition of Apellis.

Chris ViehbacherPresident and CEO

You've seen strong double-digit growth for both the full quarter and year to date for the combined sales of those two products. Now we're only consolidating the revenue from the 14th of May when we closed the transaction. Those products are already contributing significantly to our own growth. I'll take the opportunity here just to note that if I think about all of the integrations that I've certainly seen over my career one of the most important metrics is really how revenue does through this period of turbulence really in organizations. There's an awful lot of uncertainty that comes from these major transactions. The ability to maintain continuity of revenue is, I think, the number 1 measure of the success of an integration. I think so far that we have seen that, and that's really because this is mostly a U.S. transaction.

Chris ViehbacherPresident and CEO

This is really a credit to Alisha Alisha's leadership and her team in really reaching out and making sure that the Apellis team feels great about joining Biogen. Certainly, when I talk to the former Apellis, now Biogen employees, one sense is a sense of energy and passion and commitment. We're very much encouraged by the importance of this acquisition. The next slide is really, again, Priya is going to talk a lot more about this, but we've got a growing base, and now we've got five registrational phase III clinical trial results coming along. Obviously, two in SLE for lupus, one in CLE for lupus, one for AMR and one which is really from our partner at Stoke in Dravet syndrome. Those are now within the next four quarters.

Chris ViehbacherPresident and CEO

These are imminent and could really make a difference to the long-term growth outlook of Biogen. As we talked about before, we're also rebuilding our early-stage pipeline. We went 3 years really without filing an IND. We made some really pretty dramatic moves to overhaul our research organization, how we do research. The encouraging thing is that I think we are now in a much better place already in our early-stage pipeline. Some of that is coming early. We've had 3 INDs already this year. We've got more to come. We've done a number of key collaborations like Vanqua and Dayra last year, the acquisition of RayThera this year also substantially boosts our early-stage pipeline. This is really investing today for really what would be products launching in the mid-2030s. You've got to start today if you want to have that growth tomorrow.

Chris ViehbacherPresident and CEO

If I look at this slide, this is a slide we first showed at J.P. Morgan earlier this year. At that time, we said, "Look, there are a number of near-term current growth drivers," and you see them with LEQEMBI and ZURZUVAE, VUMERITY, SPINRAZA, SKYCLARYS and QALSODY. That is the group of products that now exceed our legacy MS portfolio and grew strongly in the quarter. When you add SYFOVRE and EMPAVELI, these products already in themselves are enough to help Biogen get back to a growth story. When you look at what's coming, we just talked about these imminent data readouts. That's the second wave here, the registrational late-stage pipeline. These are all products with significant opportunity. This is also a major shift for Biogen. 3 and a half years ago when I came, we really only were visiting the neurologist.

Chris ViehbacherPresident and CEO

We had a few products that we could still promote in MS, and we had SPINRAZA. We are now looking at visiting rheumatologists, dermatologists, nephrologists outside the U.S., epileptologists, and nephrology transplants. There's been a significant growth in the breadth of our portfolio. That's exciting. It also means that really now we are shifting to not just growing the substrate of growth, but now executing on that growth story. There's a lot going on inside the company to make sure that all of those launches are a success. We're also keeping an eye on the longer term, and that's that third wave, the opportunities for longer-term growth. diranersen, and you've seen the data on that, very promising new modality in Alzheimer's, not necessarily part of the equity story near term, but longer term, this could significantly contribute to Biogen's growth.

Chris ViehbacherPresident and CEO

This is where this renewed early-stage pipeline that I just talked about is so important and the research portfolio. From a BD M&A point of view, I think we have what we need to grow near term. I think we'll be less intentional about M&A and perhaps more opportunistic. We'll be certainly intentional about the earlier stage development. Ideally, we'd like to be bringing in assets between development candidate and IND stage. When you look at what is the opportunity, and these are not revenue forecasts, but really an initial sense of what's the addressable market that come from the pipeline, and I would say we're still doing work. We've got lupus here as a potential $8 billion market. The MS market is over $20 billion. I think we're not there yet in terms of being able to really say how we access that.

Chris ViehbacherPresident and CEO

It's probably a $2 billion-$3 billion market today, There's no real reason why this market shouldn't be the size of MS. Even if you just say the $8 billion, that's a significant opportunity for us to go after, and obviously not only with litifilimab, but we would hope to be the first product to be approved for CLE. You got AMR, approximately 11,000 patients just in the U.S. alone. Phase III data coming in early 2027. That's at least a $2 billion addressable market here. It depends on which pricing you're using, but when you see the pricing that is now occurring in IGAN, that is going to have a spillover effect on AMR. When you think about microvascular inflammation, which is another indication we're pursuing, that market could also grow.

Chris ViehbacherPresident and CEO

Of course, then later on, we've got IGAN and PMN data coming for felzartamab. Dravet syndrome, as you know, we have the ex-U.S. rights, but even in ex-U.S. markets There are about 7,000 patients in Europe alone, and when you add up all of our key Biogen territories, that's at least a $2 billion opportunity. Again, we're busy working on that. We're still, in some ways, 18-24 months from launch on those things, and continuing to work. This shows the potential. It also shows why we have to execute with excellence, and we're busy investing today to make sure those launches are a success. We go to the last slide. If you looked at Biogen pre the Apellis announcement, consensus of investors was that Biogen was going to be roughly flat through 2030.

Chris ViehbacherPresident and CEO

I think we're already seeing that consensus start to shift because people start to appreciate the Apellis transaction. The way we certainly see it is when you take the Apellis marketed products and you add them to our own growth product portfolio, I think we're seeing a growing picture. When you now then take the late-stage registration pipeline, I can remember vividly one investor in a meeting that we had just after we had announced Apellis saying, "I get it. The late-stage pipeline now comes on top of a growing basis instead of a stable basis." This slide neatly encapsulates really the strategy to return to sustainable revenue growth. With that, I'll turn it to Priya, who can talk a little bit more about that late-stage registration pipeline.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day